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Summary
Objective To study the association between serum anti-M€ulle-
rian hormone (AMH) levels and follicular development and
endocrine responses induced by increasing doses (52–121
lg/day) of a novel recombinant human FSH (rhFSH, FE 999049)
in patients undergoing in vitro fertilization (IVF)/intracytoplasmic
sperm injection (ICSI) in a GnRH antagonist protocol.
Design Secondary analysis of a randomized controlled trial with
stratified randomization according to AMH (lower stratum: 50–
149 pmol/l; higher stratum: 150–449 pmol/l).
Patients Infertile women of good prognosis (n = 265).
Measurements Follicular development and endocrine parame-
ters during controlled ovarian stimulation (COS) with rhFSH.
Results Serum FSH levels increased with increasing rhFSH
doses and steady-state levels for each dose were similar in both
AMH strata. In the whole study population, significant
(P < 0001) positive dose responses were observed for the num-
ber of follicles ≥12 mm, and serum levels of oestradiol, inhibin
B, inhibin A and progesterone at end of stimulation. In compar-
ison with the higher AMH stratum, patients in the lower AMH
stratum had significantly different slopes of the dose–response
curves for these hormones, and no clear dose-related increase
was observed for the number of follicles in these patients.
Conclusions Dose–response relationships between rhFSH and
follicular development and endocrine parameters are signifi-
cantly different for IVF/ICSI patients with lower and higher
serum AMH levels at start of COS.
(Received 3 June 2015; returned for revision 28 June 2015; finally
revised 10 July 2015; accepted 20 July 2015)
Introduction
Recombinant follicle-stimulating hormone (rFSH) preparations
indicated for controlled ovarian stimulation (COS) in women
undergoing treatment of infertility were introduced nearly two
decades ago.1 However, dose–response studies were not included
during their clinical development as the potency of daily rFSH
preparations in humans was assumed to be similar to those of
urinary FSH preparations.2 Therefore, the dose responses of
rFSH in patients undergoing in vitro fertilization (IVF) or intra-
cytoplasmic sperm injection (ICSI) treatment, especially of low
and high responder patients, have been poorly described in the
literature and are mainly extrapolated from randomized clinical
trials (RCTs) comparing two dosages of FSH preparations in
normal responders.3 Furthermore, optimal starting doses in vari-
ous patient populations have not been established prospectively.
The aim of COS is to obtain an adequate number of compe-
tent oocytes with minimum safety risks for patients.4 However,
a large variability in the ovarian and endocrine responses is a
well-known phenomenon in regular IVF/ICSI patients given a
fixed standard dose of FSH,5 because the functional ovarian
reserve, that is the pool of FSH-recruitable follicles, reflects the
woman’s reproductive age and ovarian ageing differs markedly
between individuals.6 It is therefore crucially important to indi-
vidualize COS regimens, with the aim of eliminating iatrogenic
risks, such as ovarian hyperstimulation syndrome (OHSS) due
to an excessive response, and minimizing the risk of cycle can-
cellation due to poor response.7 For this reason, several
biomarkers of ovarian reserve have been evaluated for their abil-
ity to accurately predict ovarian response to exogenous FSH
stimulation.8–10 Anti-M€ullerian hormone (AMH) is currently
considered as the most robust measure of ovarian reserve11,12
and is a better predictor of the number of oocytes retrieved
compared with other serum markers such as menstrual cycle
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day-3 FSH and basal levels of inhibin B and oestradiol,9 or
ultrasound assessment of antral follicle count (AFC).13–15
Recently, a novel rFSH (rhFSH) has been expressed for the
first time in a human cell line (PER.C6 Crucell, Leiden, The
Netherlands), while existing rFSH preparations (i.e. follitropin-a
and follitropin-b) are derived from Chinese hamster ovary
(CHO) cell lines. The amino acid sequences of the rhFSH mole-
cule are identical to the sequences of natural human FSH, but
compared with CHO-derived rFSH, the sialic acid content of
rhFSH is higher having both a2,3 and a2,6 sialylation. Accord-
ingly, it resembles natural human FSH more closely.16 Phase 1
studies in healthy women of reproductive age indicated that
rhFSH and follitropin-a, each dosed in equivalent international
units (IUs), displayed significantly different pharmacokinetic and
pharmacodynamic properties.17 Therefore, a phase 2 dose–re-
sponse trial of rhFSH was initiated in IVF/ICSI patients using a
broad range of dosages, and it was demonstrated prospectively
that a significant AMH-dependent dose–response relationship
existed between FSH exposure and the number of oocytes
retrieved.18 More interestingly, because the patients’ AMH levels
were used to stratify the randomization of potential low and
high responders in each rhFSH dose group, the dose responses
could be compared between patients with estimated lower and
higher ovarian reserve.
Using data from the recent RCT,18 the aim of this study was
to study the association between the patients’ serum AMH levels
and the rhFSH-induced follicular development and endocrine
responses including serum levels of FSH, LH, oestradiol, proges-
terone, inhibin A and inhibin B.
Materials and methods
This study is a secondary analysis of data prospectively collected
in a randomized, open-labelled, parallel-group, dose–response
phase 2 trial conducted at seven centres in four countries (Bel-
gium, Czech Republic, Denmark and Spain) from September
2011 through May 2013 (ClinicalTrials.gov Identifier:
NCT01426386). The trial was assessor-blinded, and all investiga-
tors, central laboratory personnel and sponsor staff involved in
analysing and interpreting data were kept blinded to treatment
allocation throughout the trial. The trial was performed in
accordance with the Declaration of Helsinki, the International
Conference on Harmonisation Guidelines for Good Clinical
Practice and local regulatory requirements. The study protocol
was approved by the local regulatory authorities and the inde-
pendent ethics committees covering all participating centres. All
patients provided written informed consent.
Trial population and treatment regimen
The trial enrolled good-prognosis patients, and the population,
design, methods and main outcome results are described in
detail elsewhere.18 The main inclusion criteria were as follows:
age 18–37 years; tubal infertility, unexplained infertility, infertil-
ity related to endometriosis stage I/II, or partners diagnosed
with male factor infertility; FSH 1–12 IU/l; AFC ≥6 and ≤25 for
both ovaries combined; AMH 50–449 pmol/l (07–63 ng/ml);
body mass index (BMI) 185–320 kg/m2; and regular menstrual
cycles 24–35 days. Women with known polycystic ovary syn-
drome associated with anovulation, known endometriosis stage
III–IV, poor ovarian response in a previous COS cycle using an
average daily FSH dose ≥150 IU, or excessive ovarian response
in a previous COS cycle using an average daily FSH dose
<225 IU were excluded. Screening was performed within
3 months of stimulation day 1 (randomization) for assessment
of compliance with inclusion and exclusion criteria, including
AMH assessment.
On days 2–3 of the menstrual cycle, the patients were ran-
domly assigned at equal ratios to receive fixed daily subcuta-
neous injections during the stimulation period of either 52, 69,
86, 103 or 121 lg rhFSH (FE 999049; Ferring Pharmaceuticals,
Saint-Prex, Switzerland), or 11 lg (150 IU) follitropin-a
(Gonal-F filled by mass; Merck Serono, Darmstadt, Germany)
which was included as a reference group. The rhFSH dose is
expressed in mass (lg), as the IUs assessed by the pharma-
copoeial rat bioassay (Steelman–Pohley in vivo bioassay) do not
fully reflect the response of rhFSH in humans.17 Randomization
was stratified according to the patients’ serum concentration of
AMH at screening [lower stratum: 50–149 pmol/l (07–
<21 ng/ml); higher stratum: 150–449 pmol/l (21–63
ng/ml)]. On stimulation day 6, a GnRH antagonist (ganirelix
acetate, Orgalutran, MSD) was initiated at a daily dose of
025 mg and continued throughout the stimulation period. As
soon as ≥3 follicles with a diameter ≥17 mm were observed, trig-
gering of final follicular maturation was undertaken with 250 lg
recombinant hCG (choriogonadotropin alfa, Ovitrelle; Merck
Serono) if there were <25 follicles ≥12 mm, or with 02 mg
GnRH agonist (triptorelin acetate, Decapeptyl; Ferring Pharma-
ceuticals) if there were 25–35 follicles ≥12 mm. If there were
>35 follicles ≥12 mm, the cycle was cancelled; coasting was not
allowed. If <3 follicles ≥10 mm were observed on stimulation
day 10, the cycle could be cancelled. Oocyte retrieval took place
36  2 h after triggering of final follicular maturation, and the
oocytes could be inseminated by IVF or ICSI.
Assessment of follicular development
Transvaginal ultrasound of the left and right ovary was performed
at stimulation days 1, 4, 6 and end of stimulation to count the
number of follicles and measure the size of the follicles.
Hormone assays
The serum concentration of AMH (1 pmol/l = 0140 ng/ml;
1 ng/ml = 7143 pmol/l) at screening was assessed by a central
laboratory (ICON Central Laboratories, Dublin, Ireland) using
the Beckman Coulter Gen II ELISA assay. The specimens were
kept at ambient temperature for 1–5 days prior to analysis (i.e.
during storage at the trial centre and shipment to the central
laboratory) to avoid possible complement interference. Blood
samples for endocrine monitoring were sampled at stimulation
day 1 prior to the start of stimulation, and ≥8 h after the previ-
ous administration at days 4 and 6 and end of stimulation; end
of stimulation reflects all patients receiving hCG when three fol-
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licles ≥17 mm were reached and two patients who had excessive
ovarian response leading to triggering with GnRH agonist. The
serum specimens for endocrine parameters (except AMH) were
stored individually at 18 °C at the trial centres before ship-
ment in frozen containers to the central laboratory and subse-
quent analysis in batches. An overview of the validated analytical
methods, sensitivity and precision is given in Table S1.
Statistical methods
The dose–response relationships at end of stimulation were evalu-
ated using analysis of covariance (ANCOVA) models. For each endo-
crine parameter, the observed values were log-transformed and
the model included log(dose) and log(baseline) as covariates and
AMH stratum as factor. The ANCOVA model for number of folli-
cles ≥12 mm included log(dose) as covariate and AMH stratum
and trial site as factors. To evaluate the potential difference in dose
response between the two AMH strata, an interaction term (AMH
stratum 9 log(dose)) was included in the models. In case of a sig-
nificant interaction, the models were fitted for each AMH stratum
separately and the resulting P values reported.
Results
Patient population
The study randomized 265 patients of whom 117 patients
(44%) had serum AMH <15 pmol/l (lower stratum between 50
and 149 pmol/l) and 148 patients (56%) had AMH ≥15 pmol/L
(higher stratum between 150 and 449 pmol/l). Two hundred
and twenty-two patients received one of the five doses of rhFSH
(42, 45, 44, 44 and 47 patients allocated to the 52, 69, 86, 103
and 121 lg/day groups, respectively), and 43 patients received
11 lg/day of follitropin-a. There were no clinically relevant dif-
ferences between the six treatment groups at baseline with
respect to age, body weight, BMI, AFC and AMH levels;18 the
overall mean (SD) values for the trial population were 327
(30) years, 626 (92) kg, 231 (31) kg/m2, 139 (44)
and 184 (97) pmol/l, respectively. The patients randomized
in the lower and higher AMH strata had mean (SD) AMH
levels of 96 (26) and 253 (75) pmol/l, respectively.
Follicular development during stimulation
Fig. 1 shows the follicular development. The total number of folli-
cles ≥12 mm observed at stimulation day 4, day 6 and end of stim-
ulation in all patients is shown in Fig. 1a, and in the lower and
higher AMH strata in Fig. 1b,c, respectively. The mean number of
total follicles ≥12 mm increased with the daily dose of rhFSH
administered. At end of stimulation, a significant (P < 0001)
dose-dependent increase in follicles ≥12 mm was observed
(Fig. 1d); the mean number (SD) of follicles ≥12 mm was lowest
(67  32) in the 52 lg group and highest (117  45) in the
121 lg group. The mean number of follicles ≥12 mm in the fol-
litropin-a group was 109  46. During rhFSH treatment, the
slopes of the time–response curves with respect to number of folli-
cles ≥12 mm were steeper in the patients in the higher AMH stra-
tum than in the lower AMH stratum (Fig. 1b,c). At end of
stimulation, the slopes of the dose–response curves were signifi-
cantly (P = 0044) different between the two AMH strata
(Fig. 1e). The more marked follicular responses at end of rhFSH
stimulation in patients with higher AMH were also apparent at
different size categories (Figure S1).
Serum hormone levels during stimulation
Fig. 2 shows the serum hormone levels during stimulation for
all patients in each rhFSH dose group. Prior to the first FSH
injection on stimulation day 1, the mean endogenous FSH levels
ranged from 64 to 74 IU/l in the different treatment groups;
patients with lower AMH had significantly higher FSH levels
than patients with higher AMH (77  28 IU/l vs
66  18 IU/l, P < 0001). Up to stimulation day 6, the FSH
level increased in a linear dose-dependent manner, and there-
after, it remained at steady state until the end of stimulation for
all rhFSH doses (Fig. 2a). At end of stimulation, the mean FSH
level ranged from 82 to 171 IU/l in the 52–121 lg rhFSH
dose groups, respectively, and was 101 IU/l in the follitropin-a
group. Within each rhFSH dose level, there was no difference in
the FSH levels during stimulation between the lower and higher
AMH strata (Fig. 3a,b). The dose–response relationship between
the administered dose of rhFSH and the FSH level in serum was
significant (P < 0001) at stimulation day 6 and at end of stimu-
lation, overall (Fig. 2a) and in both AMH strata (Fig. 3c,d).
The mean serum LH levels at stimulation day 1 were similar
between the rhFSH groups and ranged from 45 to 51 IU/l
prior to the first rhFSH injection. At stimulation day 4, LH
levels had declined in all five dose groups to mean values of
13–22 IU/l, overall (Fig. 2b) and in both AMH strata (Fig. 4a,
b); thereafter, mean LH levels rose on stimulation day 6 in the
two highest dose groups, especially in the higher AMH stratum.
A significant (P = 0020) dose-dependent increase in LH was
noted in this group of patients at stimulation day 6, while there
was no dose–response relationship in patients with lower AMH
(Fig. 4c). Following the administration of GnRH antagonist
starting at stimulation day 6, LH levels decreased in all rhFSH
treatment groups up to end of stimulation, when the levels ran-
ged from 13 IU/l in the lowest dose group to 10 IU/l in the
highest dose group. Within each rhFSH dose group, the mean
LH level was similar in the two AMH strata and no dose–re-
sponse relationships were noted (Fig. 4d). The mean LH level at
end of stimulation was 10 IU/l in the follitropin-a group.
Fig. 2c shows serum oestradiol levels during stimulation for
all patients in each rhFSH dose group. The oestradiol level
increased in a dose-related manner, and a significant
(P < 0001) dose-related increase was observed at the end of
stimulation, at which time the mean levels ranged from 2780 to
5651 pmol/l in the rhFSH dose groups, and was 4780 pmol/l in
the follitropin-a group. At end of stimulation, oestradiol was
considerably higher in the higher AMH stratum than in the
lower AMH stratum at all rhFSH doses, with the exception of
the lowest dose of 52 lg (Fig. 5a,b). The slopes of the rhFSH
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Fig. 1 The total number (mean  SE) of follicles ≥12 mm observed at stimulation day 4, day 6 and the end of stimulation in all patients (a), and in
subsets of patients with lower anti-M€ullerian hormone (AMH) (5–149 pmol/l) (b) or higher AMH (15–449 pmol/l) (c), during stimulation with fixed
daily doses of rhFSH. The number of follicles ≥12 mm at end of stimulation in the five rhFSH dose groups is shown for all patients (d) and by AMH
stratum (e); P values reflect the dose–response relationship. The number of follicles ≥12 mm at the end of stimulation following a fixed daily dose of
11 lg follitropin-a is added as a reference.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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Fig. 2 Serum hormone levels (mean  SE) measured at stimulation day 4, day 6 and the end of stimulation in all patients. Insert panels show the
levels at end of stimulation in the five rhFSH dose groups; P values reflect the dose–response relationship. The hormone levels at the end of
stimulation following a fixed daily dose of 11 lg follitropin-a are added as a reference.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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dose–response curves were significantly (P = 0008) different
between the AMH strata (Fig. 5e).
The serum progesterone levels tended to decline in all rhFSH
dose groups during the first days of stimulation followed by
gradual rises after stimulation day 4. At end of stimulation,
small, but significant (P < 0001), dose-related increases were
observed in the whole rhFSH population (Fig. 2d) and in the
higher AMH stratum (Fig. 5f), although the mean progesterone
levels remained below 10 ng/ml in all dose groups. At end of
stimulation, the slope of the dose–response curve in the lower
AMH stratum was significantly (P = 0012) lower than that of
the higher AMH stratum, and no dose-related increase in pro-
gesterone was observed in the women with lower AMH (Fig. 5f).
In the follitropin-a group, the mean serum progesterone level at
end of stimulation also remained below 10 ng/ml.
Fig. 2e,f shows serum inhibin B and inhibin A levels during
stimulation for all patients in each rhFSH dose group. The levels
of both hormones increased with the rhFSH dose, and signifi-
cant dose responses were observed at end of stimulation
(P < 0001), at which stage the mean levels of inhibin B were
403, 664, 793, 720, 773 ng/l and mean levels of inhibin A 167,
234, 303, 301, 348 ng/l in the 52, 69, 86, 103, 121 lg rhFSH
groups, respectively, and 726 and 278 ng/l, respectively, in the
follitropin-a group. In both AMH strata, the increases in inhibin
B flattened after day 6 in the higher rhFSH dose groups (Fig. 6a,
b), whereas inhibin A levels continued to rise markedly in all
dose groups (Fig. 6c,d). Compared to patients in the higher
AMH stratum, no clear dose response was observed for inhibin
B in patients in the lower AMH stratum (Fig. 6e). In contrast,





Fig. 3 Serum FSH levels (mean  SE) measured at stimulation day 4, day 6 and the end of stimulation in subsets of patients with lower anti-
M€ullerian hormone (AMH) (5–149 pmol/l) (a) or higher AMH (15–449 pmol/l) (b). The serum FSH levels at day 6 (c) and at end of stimulation (d)
in the five rhFSH dose groups are shown for each AMH stratum; P values reflect the dose–response relationship. Serum FSH levels at end of
stimulation following a fixed daily dose of 11 lg follitropin-a are added as a reference.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2015), 83, 902–912
rhFSH stimulation and endocrine responses 907
end of stimulation were observed in both AMH strata, although
the magnitude of the inhibin A rise was lower in the lower
AMH stratum (Fig. 6f).
Discussion
Until recently, there were no adequately powered dose–response
studies of daily administration of gonadotrophins in IVF/ICSI
patients to provide relevant information on the relation between
FSH exposure and ovarian response during COS. In fact, this is
the first randomized dose–response trial of daily recombinant
FSH treatment in which the ovarian response was studied
prospectively over a broad dose range. Moreover, the randomiza-
tion was stratified for AMH with the aim of having a balanced dis-
tribution of patients with estimated lower and higher response in
each dose group. The present study demonstrated significant posi-
tive relationships between the daily dose of rhFSH in the range of
52–121 lg and follicular development and endocrine responses.
Subset analysis showed that these relationships were more appar-
ent in patients with higher than with lower AMH levels.
In line with the pharmacokinetic properties of rFSH expressed
by a CHO cell line,19 serum FSH levels increased in a linear
dose-dependent manner following daily injections of rhFSH.
Hence, the number of follicles ≥12 mm increased in all dose
groups and a significant dose response was observed at end of
stimulation, consistent with the primary end-point of this trial
showing a highly significant relationship between the dose and
the number of oocytes retrieved.18 In the present study, it is
shown that the degree of ovarian response in patients with lower





Fig. 4 Serum LH levels (mean  SE) measured at stimulation day 4, day 6 and the end of stimulation in subsets of patients with lower anti-M€ullerian
hormone (AMH) (5–149 pmol/l) (a) or higher AMH (15–449 pmol/l) (b). The serum LH levels at day 6 (c) and at end of stimulation (d) in the five
rhFSH dose groups are shown for each AMH stratum; P values reflect the dose–response relationship. Serum LH levels at end of stimulation following
a fixed daily dose of 11 lg follitropin-a are added as a reference.
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Fig. 5 Serum oestradiol levels (mean  SE) measured at stimulation day 4, day 6 and the end of stimulation in subsets of patients with lower anti-
M€ullerian hormone (AMH) (5–149 pmol/l) (a) or higher AMH (15–449 pmol/l) (b), and serum progesterone levels (mean  SE) in subsets of
patients with lower AMH (c) or higher AMH (d), during stimulation with fixed daily doses of rhFSH. The serum oestradiol (e) and progesterone (f)
levels at end of stimulation in the five rhFSH dose groups are shown for each AMH stratum; P values reflect the dose–response relationship. Serum
oestradiol and progesterone levels at the end of stimulation following a fixed daily dose of 11 lg follitropin-a are added as a reference.
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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Fig. 6 Serum inhibin B levels (mean  SE) measured at stimulation day 4, day 6 and the end of stimulation in subsets of patients with lower anti-
M€ullerian hormone (AMH) (5–149 pmol/l) (a) or higher AMH (15–449 pmol/l) (b), and serum inhibin A levels (mean  SE) in subsets of patients
with lower AMH (c) or higher AMH (d), during stimulation with fixed daily doses of rhFSH. The serum inhibin B (e) and inhibin A (f) levels at end
of stimulation in the five rhFSH dose groups are shown for each AMH stratum; P values reflect the dose–response relationship. Serum inhibin B and
inhibin A levels at the end of stimulation following a fixed daily dose of 11 lg follitropin-a are added as a reference.
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levels induced a much steeper dose–response curve in terms of
follicular development in patients with higher AMH levels than
in patients with lower AMH levels, it may be concluded that the
selection of the appropriate daily rhFSH dose is more critical for
potential high responders. In addition, adjusting the starting
gonadotrophin dose in a subsequent treatment cycle by the same
magnitude will have a larger impact on the ovarian response of
high responders than of low responders. Whereas lowering of
the daily dose of rhFSH in the next cycle is essential in high
responders, increasing the daily rhFSH dose in low responders
may only be helpful as long as the maximal ovarian response is
not yet reached. In clinical practice, low responders may often
receive much higher gonadotrophin doses than required, even
though clinical research has shown that such an approach will
not improve the number of oocytes retrieved.20,21
In the present study, the serum levels of oestradiol and inhib-
ins during rhFSH treatment reflected the number and size of
growing follicles. In line with an earlier study in normal respon-
ders,22 inhibin B levels increased markedly until stimulation day
6 after which the levels flattened or declined until end of stimu-
lation. In contrast, oestradiol and inhibin A levels kept rising
through the whole stimulation period and to much greater
extents in the patients with higher AMH levels. The different
time courses of the inhibin A and B levels were likely due to the
fact that inhibin B is mainly secreted by pre-antral and small
antral follicles, while inhibin A is predominantly produced by
pre-ovulatory follicles.23,24 Hence, once the follicles reach pre-
ovulatory sizes, the inhibin B production lowers, whereas the
inhibin A-secreting capacity continues to increase during the late
follicular phase. The noted discrepancy between the rises of inhi-
bin B and inhibin A in both AMH strata fits well with the pub-
lished literature on these levels in patients with and without
developing symptoms of OHSS.25,26
Irrespective of the degree of ovarian stimulation, there were
only slight differences between the rhFSH dose groups with
regard to their average serum LH and progesterone levels. Ini-
tially, LH levels were decreased by rhFSH administration and
subsequently by the administration of GnRH antagonist, but
there was limited overall impact of increasing rhFSH doses on
LH levels during stimulation. From stimulation day 4 onwards,
progesterone levels rose gradually, and at end of stimulation, sig-
nificant dose-related increases were observed in the whole popu-
lation and in the higher AMH stratum; however, mean levels
remained below 10 ng/ml in all dose groups, even for patients
in the higher AMH stratum. Although the average LH and pro-
gesterone levels were not so different between treatment groups,
further data are needed to establish the impact of elevated levels
in individual patients following rhFSH treatment.
Currently, a starting dose of 150 IU/day of rFSH is considered
to be the lowest effective dose in regular IVF/ICSI patients
undergoing their first treatment cycle using a GnRH antagonist
protocol. However, this daily gonadotrophin dose may be too
low or too high, leading to dose adjustments made half-way
during the treatment cycle in an attempt to increase or decrease
the number of growing follicles. However, the size of the follicle
cohort that is recruited largely depends on the starting dose,
while dose adjustments during stimulation are known to be less
effective.4 Of the patients undergoing their first IVF cycle with a
starting dose of 150 IU, over 50% need to alter the starting dose
in the second treatment cycle, which has a significant impact on
the ovarian response.27 Thus, ideally patients should receive in
their first treatment cycle a daily FSH dose already tailored to
their ovarian reserve to ensure the shortest time interval to a
successful outcome. As supported by the present trial, follicular
development and the number of retrieved oocytes18 are very dif-
ferent in patients with low and high ovarian reserve treated with
the same rhFSH dose. To select the optimal daily dose for each
patient, an individualized rhFSH dosing algorithm based on
serum AMH levels might be helpful, especially in patients
undergoing their first IVF cycle. Such an algorithm may prevent
too low or too high ovarian responses in the majority of patients
and ineffective overdosing in low responders, as well as dose
adjustments during stimulation.14,28
In line with previous findings regarding oocyte yield,18 the data
from this study suggest that the follicular and endocrine responses
at the end of stimulation are higher with rhFSH than with fol-
litropin-a when extrapolating the data to similar microgram doses
of the two compounds. The apparently large differences between
preparations in serum FSH levels (measured in this trial at least
8 h after the previous administration of gonadotropin) in relation
to the magnitude of the pharmacodynamic responses are most
likely due to the lower clearance and longer half-life of rhFSH as
determined by its characteristic glycosylation profile.17
In conclusion, significant positive dose–response relationships
were noted between administration of rhFSH and number of
follicles, and serum levels of oestradiol, inhibin B, inhibin A and
progesterone. These relationships were different for subsets of
patients with lower or higher AMH at screening. This indicates
the need for individualized rhFSH dosing based on a reliable
biomarker of ovarian reserve, such as AMH, to obtain an ade-
quate number of growing follicles and an endocrine environ-
ment that favours implantation in patients undergoing COS
prior to IVF or ICSI.
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